Employees Provident Fund Board Purchases Shares of 704,196 Biogen Inc. $BIIB

Employees Provident Fund Board acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, Holdings Channel reports. The fund acquired 704,196 shares of the biotechnology company’s stock, valued at approximately $123,931,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Reflection Asset Management bought a new position in shares of Biogen during the fourth quarter valued at approximately $25,000. WPG Advisers LLC lifted its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares during the last quarter. First Horizon Corp purchased a new stake in shares of Biogen during the fourth quarter worth about $30,000. Root Financial Partners LLC grew its holdings in shares of Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares during the last quarter. Finally, MV Capital Management Inc. purchased a new position in Biogen during the 4th quarter worth approximately $34,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Price Performance

BIIB stock opened at $196.58 on Friday. The business’s 50-day moving average is $190.80 and its two-hundred day moving average is $184.89. The firm has a market capitalization of $29.02 billion, a P/E ratio of 21.09 and a beta of 0.20. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $205.97. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts anticipate that Biogen Inc. will post 13.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BIIB. The Goldman Sachs Group boosted their target price on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Royal Bank Of Canada raised their price objective on Biogen from $222.00 to $227.00 and gave the company an “outperform” rating in a report on Wednesday, May 27th. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and upped their price target for the company from $185.00 to $225.00 in a research report on Wednesday, April 22nd. Sanford C. Bernstein cut their price objective on shares of Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. Finally, HSBC lifted their target price on Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $217.37.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s planned RayThera acquisition expands its immunology pipeline with multiple anti-inflammatory assets, which could improve future growth opportunities and make the company less dependent on a single therapeutic area. Reuters article
• Positive Sentiment: Needham reiterated a Buy rating and set a $255 price target, signaling that some analysts see the deal as supportive of Biogen’s long-term earnings potential. TipRanks article
• Positive Sentiment: Morgan Stanley raised its price target on Biogen to $224 from $206, which may have helped reinforce bullish sentiment around the stock. Benzinga article
• Neutral Sentiment: Biogen shares were also reported to be outperforming peers even as broader healthcare stocks declined, suggesting relative strength rather than a company-specific selloff. MarketWatch article
• Negative Sentiment: An investor alert from Pomerantz LLP disclosed an investigation into claims on behalf of Biogen investors, which could add legal overhang and keep some pressure on sentiment. PR Newswire article

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.